Latest News

• share
• favorite_border

Researchers from Roswell Park Comprehensive Cancer Center will present the latest results of clinical trials and insights on cancer treatment and issues affecting patients with cancer, including the financial burdens induced by cancer treatment, at the annual meeting of the American Society of Clinical Oncology (ASCO), which will take place both online and in-person in Chicago, Illinois, from June 3 to 7.

• share
• favorite_border

Several nursing teams from Roswell Park Comprehensive Cancer Center were invited to share their research at the 47th Annual Congress of the Oncology Nursing Society (ONS), which is underway in Anaheim, California, and continues through May 1, 2022.

• share
• favorite_border

oswell Park Comprehensive Cancer Center specialists will share the latest advances and developments in the treatment of blood-related cancers at the 2022 Tandem Transplantation & Cellular Therapy Meetings of American Society for Transplantation and Cellular Therapy (ASTCT) and Center for International Blood and Marrow Transplant Research (CIBMTR) in Salt Lake City, Utah, from April 23 to 26.

• share
• favorite_border

The University at Buffalo will lead a $10 million project to develop software that academia, industry and government agencies use to manage high-performance computing infrastructure, the U.S. National Science Foundation (NSF) announced on Friday.

• share
• favorite_border

New data to be presented by Grace Dy, MD, at the American Association for Cancer Research Annual Meeting show that patients with non-small cell lung cancer (NSCLC) who received the targeted therapy sotorasib experienced extended survival and good quality of life.

• share
• favorite_border

Combining a beta-blocker with the cancer immunotherapy drug pembrolizumab could be a promising new treatment option for many hard-to-treat solid-tumor cancers. Researchers from Roswell Park Comprehensive Cancer Center will report on a study of of this treatment combination in patients with advanced or metastatic melanoma at the American Association for Cancer Research (AACR) Annual Meeting 2022.

• share
• favorite_border

Two Roswell Park Comprehensive Cancer Center oncologists will discuss promising strategies for making breakthrough immunotherapies work for more patients at the annual meeting of the American Association for Cancer Research (AACR) in New Orleans, Louisiana, on Monday, April 11.

• share
• favorite_border

Dozens of cancer specialists at Roswell Park Comprehensive Cancer Center have been invited to present their latest advances in cancer research at the annual meeting of the American Association for Cancer Research (AACR), which will take place in New Orleans, Louisiana, from April 8 to 13.

• share
• favorite_border

Roswell Park Comprehensive Cancer Center has been designated as an LGBTQ+ Healthcare Equality Leader on the Human Rights Campaign Foundation’s Healthcare Equality Index (HEI) 2022, earning the maximum score in each area evaluated.

• share
• favorite_border

• share
• favorite_border

In 1873, Russian doctor J. von Rusitzky coined the term “multiple myeloma” after finding eight different types of bone marrow tumors in a single patient. Nearly 150 years later, using advanced cell sequencing technology and state-of-the-art imaging techniques, researchers at Roswell Park Comprehensive Cancer Center have provided a molecular and biological explanation for this finding, discovering that different myeloma clones can be present in a single patient and linking these distinct genetic changes in myeloma cells to the development of myeloma bone disease.

• share
• favorite_border

Roswell Park Comprehensive Cancer Center is the first center to treat patients in a newly opened advanced-stage clinical trial utilizing the brain cancer vaccine SurVaxM, offering a new treatment option for patients who are dealing with a rare but deadly form of the disease. The multicenter randomized clinical trial is sponsored by MimiVax LLC, a company spun off from Roswell Park in 2012.

• share
• favorite_border

Scientists at Roswell Park Comprehensive Cancer Center have identified a potential new target for the treatment of pancreatic cancer. The study, published today in Cancer Cell, outlines the team’s discovery of a fungus-activated pathway that fuels the production of a molecule present in cancerous cells in the pancreas, opening a possible new treatment avenue for patients with this devastating disease.

• share
• favorite_border

Since the introduction of electronic cigarettes, or e-cigarettes, to the United States in 2006, intense debate has surrounded the marketing, regulation and use of these nicotine-delivery products.

• share
• favorite_border

An international research team co-led by scientists at Roswell Park Comprehensive Cancer Center and The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute has identified an important accelerator of treatment-resistant prostate cancer. The study, published today in Cell Reports, provides insight into how loss or mutation of the NCOR2 gene accelerates the progression of prostate cancer to a more lethal form of the disease.

• share
• favorite_border

Roswell Park Comprehensive Cancer Center hematology experts in leukemia, lymphoma and other specialties will present new research at the 63rd annual meeting of the American Society of Hematology (ASH), which begins today in Atlanta, Georgia. The many research projects to be highlighted include breakthrough research on CAR T cell therapy, immunotherapy, leukemia, lymphoma and the management of genetic mutations in aggressive and rare blood cancers.

• share
• favorite_border

Roswell Park Comprehensive Cancer Center is one of three lead centers part of an international multicenter team that has recently been awarded $10 million to study how tobacco control policies impact smoking, vaping and the use of other nicotine products.

• share
• favorite_border

Stress can have a significant negative effect on health, but our understanding of how stress impacts the development and progression of cancer is just beginning. A team from Roswell Park Comprehensive Cancer Center has identified an important mechanism by which chronic stress weakens immunity and promotes tumor growth. Their findings, just published in Cell Reports, point to the beta-adrenergic receptor (β-AR) as a driver of immune suppression and cancer growth in response to stress, opening the possibility of targeting this receptor in cancer therapy and prevention.

• share
• favorite_border

For years, scientists at Roswell Park Comprehensive Cancer Center and the University of Chicago Medicine Comprehensive Cancer Center have devoted themselves to research to better understand ovarian cancer.